AASLD: Protease Inhibitors Open New Front on HCV
15th Nov 2005, 15:54 GMT
SAN FRANCISCO - Two investigational protease inhibitors appear to be highly active against hepatitis C viral infections, and both show good safety and tolerability profiles.
AASLD: Protease Inhibitors Open New Front on HCV related news:
- Procyon reports new data for its lead HIV protease inhibitor, PPL-100, showing a potentially high genetic barrier against the HIV virus — Operations-Related News from StratCenter.com
- AASLD: Schizophrenics and Drug Abusers Get Short Shrift in HCV Therapy — MedPage Today Gastroenterology
- [Biochemistry] Structural basis of the resistance of an insect carboxypeptidase to plant protease inhibitors — Proceedings of the National Academy of Sciences recent issues
- Intarcia Therapeutics Announces Interim Results From a Phase 2 Study of Omega Interferon in HCV — Bio-Technology News from StratCenter.com
- AASLD: Peg-Interferon and Ifn-Ribavirin Combo Keep HCV in Check Long Term — MedPage Today Infectious Disease
- AASLD: Weight-Based Dosing of Rebetol Improves Outlook for HCV — MedPage Today Gastroenterology
- AASLD: Consensus Interferon Plus Ribavirin Gives HCV Patients Second Chance — MedPage Today Infectious Disease
- Positive phase I trial for Schering-Plough HCV treatment — Pharmaceutical Business Review Online
- New drugs in the pipeline for public health diseases — Medical News Today RSS/XML Feed
- COX-2 Inhibitors and Other NSAIDs Increase Mortality in Acute MI Patients — Medscape FamilyMedicine Headlines
Latest news from MedPage Today.com Latest Headlines:
- ACAAI: Rodent Exposure Linked to High Asthma Rates in Children
- ACR: Lupus Increases Pregnancy and Disease-Related Risks
- ACAAI: Rush Immunotherapy Provides Rapid Results Safely
- ACR: Small Weight Loss Equals Big Gains In Osteoarthritis Quality Of Life
- Care Found Lacking for Many With Obstructive Lung Disease
- AHA: Actos (pioglitazone) May Slow Progression of Atherosclerosis
- AHA: No Benefit from Late Revascularization After MI for Stable Patients
- AHA: When Stents Fail, Send in the Drug-Coated Balloons
- AHA: When Stents Fail, Send in the Drug-Coated Balloons
- Higher Hemoglobin Targets for Chronic Kidney Disease Linked to Heart Complications